Sepracor Disputes Patent On Wyeth's Pristiq
NEW YORK (AP) ¿ Sepracor Inc. on Friday took a step toward a potential challenge of patents supporting Pristiq, an antidepressant marketed by Wyeth.
Sepracor says it discovered the drug first and filed an application for a patent in April 1999, almost two years before Wyeth made its first filing in February 2001. The Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office plans to hear arguments from the two companies on Jan. 6, 2010.
Sepracor says the patent interference is between two patents awarded to Wyeth, and three given to Sepracor.
The board will rule on who invented the drug first and who will hold the patents. If the board rules in favor of Sepracor, it could be awarded a patent on Pristiq and potentially sue Wyeth for patent infringement.Doug Petkus, a spokesman for Wyeth, said his employer would win the challenge. "Wyeth will prove during the upcoming proceedings before the patent office that we invented desvenlafaxine and that Sepracor's position is without merit," he said.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV